

COVID-19 Vaccine General Competency EXAMPLE Exam

Refer to the CDC website for continually updated information, particularly noting the *Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Authorized in the U.S.* by clicking [here](#).

- COVID-19 vaccination providers should refer to the Emergency Use Authorization (EUA) Fact Sheet for Healthcare Providers, prescribing information and manufacturer's information for detailed storage and handling of vaccines.**
 - True
 - False
- When reporting storage unit temperatures, it is best practice to record:**
 - Minimum / maximum temperature
 - Date and Time
 - Name of person checking and recording temperature
 - All are correct
- If a vaccine is stored at a temperature outside the range recommended by the manufacturer, the provider should contact the manufacturer, report the excursion using the [IHS COVID-19 Vaccine Temperature Excursion Worksheet](#), and continue to use the vaccine until the provider receives manufacturer guidance.**
 - True
 - False
- Always check the expiration date and beyond-use date (BUD) of the vaccine (and diluent if applicable) before preparing the product for administration and go by whichever date is EARLIER.**
 - True
 - False
- If a vaccine gets a shorter expiration date (also known as "beyond-use date" or "BUD") due to a change in storage temperature (i.e., transitioning storage from freezer to refrigerator as appropriate), the vaccine should be labeled with an updated BUD immediately. These labels can be found on the [CDC Website](#) for [Pfizer](#), [Moderna](#), [Novavax](#).**
 - True
 - False
- It is recommended to pool excess vaccine volume from multiple vials to make a full dose.**
 - True
 - False
- Patients who are immunocompromised, pregnant, breast-feeding, or have history of a resolved COVID-19 infection can generally be offered COVID-19 vaccines.**
 - True
 - False
- Which vaccines cannot be co-administered on the same day as the COVID-19 vaccine?**
 - Influenza vaccine
 - Shingles vaccine
 - Tetanus vaccine
 - None of the above; COVID-19 vaccines may be administered with other vaccines without regard to timing
- Which of the following would be a contraindication to receive a COVID-19 vaccine for an individual?**
 - History of an immediate allergic reaction of any severity to non-COVID-19 vaccines or injectables
 - History of anaphylaxis due to any cause (unrelated to COVID vaccine components)
 - History of immediate/severe allergic reaction to polyethylene glycol (PEG) receiving Pfizer or Moderna
 - History of immediate/severe allergic reaction to polysorbate receiving Novavax
 - Both (c) and (d) are correct
 - All of the above are correct
- According to CDC recommendations, COVID-19 vaccination does not need to be delayed following the receipt of monoclonal antibodies or convalescent plasma.**
 - True
 - False
- What site do vaccine providers use to report adverse events?**
 - <https://vaers.hhs.gov>
 - <https://www.cdc.gov>
 - <https://immunize.org>
- Unvaccinated individuals previously infected with SARS-CoV-2 and/or that demonstrate positive antibody titers do NOT need to consider COVID-19 vaccination.**
 - True
 - False
- When reporting an adverse event to VAERS relating to a vaccine within the Indian Health Service at Federal, Tribal or Urban sites, it is important to type "IHS" in item #26 in the VAERS report so that IHS can properly receive and review these submissions.**
 - True
 - False

14. Regarding the “Fact Sheet for Recipients and Caregivers”, the vaccination provider MUST:

- a. Provide a copy of the Fact Sheet
- b. Direct the recipient/caregiver to the manufacturer’s webpage or the FDA webpage to obtain the Fact Sheet
- c. Any of the above are correct
- d. None of the above; providing the Fact Sheet is NOT Required

15. The vaccination provider is responsible for mandatory reporting of the following that occur post-administration of this vaccine to the Vaccine Adverse Event Reporting System (VAERS):

- a. Vaccine administration errors, even if no adverse event occurred
- b. Serious adverse events (life-threatening, death, hospitalization, etc.)
- c. Cases of myocarditis or pericarditis (for mRNA vaccines)
- d. Cases of Multisystem Inflammatory Syndrome (MIS) in adults
- e. Case of COVID-19 that result in hospitalization or death
- f. All of the above are correct

Vaccine Provider’s Printed Name

Signature

Date